NMN vs NAD+: Can You Just Take NAD+ Directly?

Comparison Guide · Updated June 2026

If your goal is higher cellular NAD+ levels — and that is why people take NMN — a reasonable question is: why not take NAD+ directly? It seems more efficient than taking a precursor and relying on your body to convert it. This guide explains why that logic, while intuitive, misunderstands the biology — and why NMN is the scientifically supported and, in Australia, regulatory-preferred route.

Why You Cannot Just Take NAD+ Orally

NAD+ is a large molecule (molecular weight 663 Da). When you swallow NAD+ orally, it faces two problems that prevent it from raising cellular NAD+ effectively:

1. Digestive degradation: NAD+ does not survive the digestive tract intact. Enzymes in the gut (including CD38 and other NAD+-consuming enzymes on the intestinal cell surface) rapidly degrade oral NAD+ before it can be absorbed as an intact molecule.
2. Cell membrane impermeability: Even if NAD+ survived digestion, it cannot cross cell membranes intact — it is too large and hydrophilic to pass through lipid bilayers. Cells have no dedicated transporter for intact NAD+.

The bottom line: oral NAD+ supplements do not raise cellular NAD+ levels in any clinically meaningful way. Studies comparing oral NAD+ to NMN consistently find NMN superior at raising intracellular NAD+. Oral NAD+ products may raise NAD+ metabolites measurably in blood, but this is not the same as raising cellular NAD+ for mitochondrial use.

What About NAD+ IV Infusions?

NAD+ IV infusions bypass the digestive problem by delivering NAD+ directly into the bloodstream. These are available at some Australian wellness clinics (particularly in Sydney, Melbourne, and Brisbane) and do produce measurable NAD+ increases. But they come with significant practical limitations:

• Cost: $300–$800 AUD per session at Australian clinics. Weekly infusions for meaningful sustained effect = $1,500–$3,000/month.
• Administration: Requires clinical setting, qualified practitioner, 1–4 hour infusion time per session.
• Evidence: The research base for IV NAD+ is more limited than for oral NMN — fewer published placebo-controlled trials, less long-term data.
• Side effects: IV NAD+ infusions commonly cause nausea, flushing, and chest tightness during administration. These are temporary but unpleasant.

For most people, IV NAD+ is impractical for daily maintenance use. It has a role in clinical settings and for specific acute interventions, but it is not a substitute for daily oral NMN for the purposes of sustained cellular NAD+ restoration.

Why NMN Is the Evidence-Based Route

NMN solves the oral delivery problem that NAD+ cannot. NMN is a smaller molecule (334 Da) that:

• Survives the digestive tract largely intact in a delayed-release capsule
• Is actively absorbed in the small intestine via the Slc12a8 transporter — a dedicated intestinal NMN transporter discovered in 2019 by Shinichiro Imai at Washington University
• Converts to NAD+ inside cells via a single enzymatic step (NMNAT enzymes)
• Raises intracellular NAD+ measurably in human clinical trials at 250–500mg/day

This is why NMN — not oral NAD+ — is what David Sinclair takes, what the human trials use, and what the evidence supports for oral supplementation.

The Australian Regulatory Dimension

In December 2025, Australia's TGA approved NMN as a therapeutic ingredient — the first country in the world to do so. Oral NAD+ supplements have no equivalent TGA approval as a therapeutic ingredient.

The TGA's decision to approve NMN specifically — rather than NAD+ — reflects the evidence base: NMN has the human trial evidence, the delivery mechanism, and the safety profile that supports therapeutic use. Oral NAD+ supplements remain available as general health products but without the regulatory backing that NMN now has in Australia.

For Australians choosing between NMN and NAD+ supplements: the evidence, the delivery mechanism, and the Australian regulatory framework all point to NMN.

FAQ

Can you take NAD+ directly as a supplement?

Oral NAD+ supplements exist but are largely ineffective — NAD+ does not survive digestion intact to any meaningful degree. IV NAD+ infusions work but are expensive, require clinical administration, and have limited long-term evidence compared to oral NMN. For most people, NMN is the practical, evidence-supported route to raising cellular NAD+.

Is NMN better than NAD+ supplements?

Yes. NMN is a smaller molecule absorbed intact via the Slc12a8 transporter and converts to NAD+ in one step inside cells. Oral NAD+ largely degrades before reaching cells. Multiple human trials have confirmed NMN raises intracellular NAD+; oral NAD+ has no equivalent evidence base.

What about NAD+ IV infusions in Australia?

They work but cost $300–$800/session, require clinic visits, and cause side effects during infusion. For most people, daily oral NMN at $95/month is more practical, better evidenced, and sustainable long-term.

References: Imai SI et al., Nature Metabolism (2019) — Slc12a8 transporter discovery; Yoshino M et al., Cell Metabolism (2021); tga.gov.au. Not medical advice.